Skip to main content
European Commission logo print header

Smartphone Measured Eye-Based Digital Biomarkers for Drug Use Detection

Project description

Eye-based biometrics for drug testing

Nearly 30 million people are problematic drug users. The EU-funded project PrevictDrugs provides an innovative medical device for continuous, voluntary, self-monitoring of drug use. It serves as an add-on to Kontigo Care’s current eHealth offer developed for management of other addictive disorders, including alcoholism and reckless gambling. Using smartphone cameras, patients suffering from drug addiction will be identified, and asked to record a 10-second long video of their eyes. The analysis of eye biomarkers yields instant results. The project is already preparing to commercialise their product.

Objective

Drug addiction is a global problem; nearly 30 million illicit drug users worldwide suffer from problematic drug use. Kontigo Care AB is developing an innovative medical device – Previct Drugs - a robust, app-based, eHealth-platform for place unbound, continuous, voluntary, self-monitoring of drug use. It will constitute an add-on to Kontigo Care’s current eHealth offer developed for management of other addictive disorders (alcohol abuse and hazard gambling). Using smartphone cameras, patients suffering from drug addiction, will be identified, and asked to record a 10 s long video of their eyes. Analysis of eye biomarkers associated with pharmacodynamically induced pupil reactions (pupillometry) will yield instant results on drug use/sobriety.
Our unique, disruptive Internet of Thing (IoT)-based approach is designed to combine continuous monitoring of drug use and daily mood/cravings, with communication tools aimed at improving the impact of distance care. Real-time results become instantly available to caregivers through our cloud-based Care Portal, allowing fast interventions and correct patient prioritisation. This eHealth solution will drive healthcare digitalisation resulting in extreme cost-efficiency of out-patient treatments as well as convenience and complete privacy during drug screenings. A sophisticated AI-system will assess personal risks of relapse and transform addiction management to become proactive instead of reactive. This approach has the potential to enhance personalised therapy outcomes by ensuring that help can be provided fast to the patients who need it the most. The project objective is to prepare for commercialisation of the Previct Drugs module by determining the most efficient routes for gaining clinical and market acceptance by validating the product in clinical settings.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

æ

Coordinator

KONTIGO CARE AB
Net EU contribution
€ 50 000,00
Address
Pavel snickares grand 12
753 20 Uppsala
Sweden

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Östra Sverige Östra Mellansverige Uppsala län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 21 429,00